Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans

Lia Van Zuylen*, Jaap Verweij, Kees Nooter, Eric Brouwer, Gerrit Stoter, Alex Sparreboom

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Multidrug resistance (MDR)-1-P-glycoprotein (P-gp) is a drug- transporting protein that is abundantly present in biliary ductal cells and epithelial cells lining the gastrointestinal tract. Here, we have determined the role of P-gp in the metabolic disposition of the antineoplastic agent docetaxel (Taxotere) in humans. Pharmacokinetic profiles were evaluated in five cancer patients receiving treatment cycles with docetaxel alone (100 mg/m2 i.v. over a 1-h period) and in combination with a new potent inhibitor of P-gp activity, R101933 (200-300 mg b.i.d.). The terminal disposition half- life and total plasma clearance of docetaxel were not altered by treatment with oral R101933 (P ≥ 0.27). The cumulative fecal excretion of docetaxel, however, was markedly reduced from 8.47 ± 2.14% (mean ± SD) of the dose with the single agent to less than 0.5% in the presence of R101933 (P = 0.0016). Levels of the major cytochrome P450 3A4-mediated metabolites of docetaxel in feces were significantly increased after combination treatment with R101933 (P = 0.010), indicating very prominent and efficient detoxification of reabsorbed docetaxel into hydroxylated compounds before reaching the systemic circulation. It is concluded that intestinal P-gp plays a principal role in the fecal elimination of docetaxel by modulating reabsorption of the drug after hepatobiliary secretion. In addition, the results indicate that inhibition of P-gp activity in normal tissues by effective modulators, and the physiological and pharmacological consequences of this treatment, cannot be predicted based on plasma drug monitoring alone.

Original languageEnglish
Pages (from-to)2598-2603
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number7
Publication statusPublished - 1 Jul 2000
Externally publishedYes

Cite this

Van Zuylen, L., Verweij, J., Nooter, K., Brouwer, E., Stoter, G., & Sparreboom, A. (2000). Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clinical Cancer Research, 6(7), 2598-2603.